ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 26 Oct, 15:58 UTC

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.

science

Sources

• T2ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ dataBioPharma Dive / Healthcare Dive / MedTech Dive26 Oct, 15:58